Agios Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 386
- Market Cap
- $2.6B
- Website
- http://www.agios.com
- Introduction
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
- Conditions
- Sickle Cell Disease
- Interventions
- Other: Mitapivat-matching placebo
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 286
- Registration Number
- NCT05031780
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇰🇪KEMRI CRDR Clinical Research Clinic Nairobi, Nairobi, Kenya
🇱🇧Nini Hospital, Tarablus, Liban Nord, Lebanon
Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008
- Conditions
- Pyruvate Kinase Deficiency
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04995315
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇮🇹Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)
- Conditions
- Anemia, HemolyticPyruvate Kinase DeficiencyPyruvate Kinase Deficiency AnemiaAnemia
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04964323
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇮🇹Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
- Conditions
- Non-Transfusion-dependent Alpha-ThalassemiaNon-Transfusion-dependent Beta-Thalassemia
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT04770753
- Locations
- 🇸🇦
King Abdulaziz Hospital - Al Ahsa, Al-Mubarraz, Saudi Arabia
🇺🇸San Diego Hospital, UC San Diego Health, La Jolla, California, United States
🇺🇸Stanford Medicine, Palo Alto, California, United States
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
- Conditions
- Transfusion-dependent Alpha-ThalassemiaTransfusion-dependent Beta-Thalassemia
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT04770779
- Locations
- 🇺🇸
Penn Medicine - University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇮🇹Ospedale Pediatrico Microcitemico, Cagliari, Italy
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04696393
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04565678
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Dallas, Texas, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease
- Conditions
- Healthy VolunteersAnemia, Sickle Cell
- Interventions
- Drug: AG-946 Matched Placebo
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT04536792
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo for Treatment ADrug: Placebo for Treatment CDrug: Placebo for Treatment B
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04472832
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04145128
- Locations
- 🇺🇸
WCCT GLobal, Cypress, California, United States